- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04935528
Mechanisms of Anti COVID-19 Humoral and Cellular Immune Response After Vaccination in a Sample of Patients and Salaried Staff From a French Anti-cancer Center (CANSEROVAX)
Study of Mechanisms of Anti COVID-19 Humoral and Cellular Immune Response Between 1 and 3 Months After Vaccination in a Sample of Patients and Salaried Staff From a French Anti-cancer Center
Special populations are people with a risk to dévelop severe forms of a disease. The immunogenicity and efficacy of vaccines in this population may be different compared of the general population.
For Covid-19, special populations are people with chronic diseases (obesity, diabetes, cancer, etc.) and / or immunocompromised and / or elderly. It is therefore important that the safety of new vaccines as well as their efficacy be evaluated.
Thus, in cancer, most immunosuppressions and immunosuppressive treatments (in particular chemotherapy or certain targeted therapies) risk negatively impacting the effectiveness of the anti-SARS-COV-2 vaccine both for the humoral immune responses (antibodies ) and cellular (T lymphocytes). These patients may develop an insufficient post-vaccination immunity. However, it seems that immunosenescence (ie the aging of the immune system) has little impact on the effectiveness of mRNA vaccines and viral vector vaccines.
The Canserovax study evaluates the impact of anticancer treatments on the quality of the humoral (development of antibodies) and cellular (development of a specific T response) immune response to SARS-CoV-2 in patients treated for cancer after vaccination. It is carried out in patients undergoing treatment and in subjects not suffering from cancer, and not treated for this pathology (vaccinated salaried staff of a french cancer center). The aim is to qualitatively and quantitatively compare the post-vaccination immune responses in these 2 populations.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The main objective of this study is to describe after anti-SARS-CoV-2 vaccination the humoral immune response against the virus (assay of anti-SARS-CoV-2 antibodies to detect the presence and intensity of humoral immune responses) and the cellular response against the virus (specific T response).
Several cohorts are studied:
- Cohort 1 of vaccinated salaried staff (First group : Employees vaccinated with two doses of vaccine (2 Pfizer doses or 2 Astra doses or 1 Pfizer dose + 1 Astra dose) and never infected with SARS-CoV-2) and second group (Employees vaccinated with one dose of Pfizer or Astra vaccine and previously infected with SARS-CoV-2)
- Cohort 2 of unvaccinated salaried staff (controls)
- Cohort 3 of vaccinated cancer patients (metastatic colorectal, metastatic pancreas and metastatic breast cancer)
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Emilie REDERSTORFF
- Email: erederstorff@cgfl.fr
Study Contact Backup
- Name: Sylvain LADOIRE, PU-PH
- Phone Number: 03 80 73 75 06
- Email: sladoire@cgfl.fr
Study Locations
-
-
-
Dijon, France, 21079
- Centre Georges Francois Leclerc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria :
Group 1
- Salaried staff of the Georges-François Leclerc center over 18 years old
- Subject vaccinated against SARS-CoV-2 for at least 1 month (last injection), AND less than 4 months (last injection).
- Subject who gave his consent to this study
- Subject affiliated to a social security scheme
Group 2
- Salaried staff of the Georges François Leclerc center over 18 years old
- Subject not vaccinated against SARS-CoV-2
- Subject having presented a proven infection by SARS-CoV-2 (PCR)
- Subject who participated in the canSEROcov study with a positive serology result
- Subject who gave his consent to this study
- Subject affiliated to a social security scheme
Group 3
Patient over 18 years of age treated in Oncology at the GF Leclerc center for:
- Metastatic colorectal cancer beyond the first line of treatment
- Metastatic pancreatic cancer as the first line of treatment
- Metastatic breast cancer treated with anti-CDK4 / 6 + hormone therapy, or localized breast cancer treated with (neo) adjuvant chemotherapy
- Patient vaccinated against SARS-CoV-2 for at least 1 month (last injection), AND less than 4 months (last injection) with a vaccination performed when the anti-cancer treatment had been started for at least 1 month (last injection) ) (see diagram below)
- Patient having signed the informed consent for the study
- Patient affiliated to the social security scheme
Exclusion Criteria:
Groups 1, 2 and 3
- Minor or under legal protection
- Person deprived of liberty or under guardianship (including curatorship)
- Inability to undergo medical monitoring of the trial for geographical, social or psychological reasons (filling in the questionnaire and taking the blood sample)
- Refusal of the patient or employee to participate
- pregnant or breastfeeding woman
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: non vaccined salaried staff (group 2 - witnesses)
non vaccined salaried staff group wtih positive SARS-CoV-2
|
27 mL blood sample to study the humoral and the cellular immune response
|
Other: vaccined patients (group 3)
vaccined patient group
|
27 mL blood sample to study the humoral and the cellular immune response
|
Other: vaccined salaried staff (group 1)
vaccined salaried staff group (Distinction between
|
27 mL blood sample to study the humoral and the cellular immune response
7 mL blood sample to study the humoral response
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
seroprevalence of SARS-CoV-2 and ELISPOT
Time Frame: through study completion, an average of 1 year
|
rate of specific SARC-Cov-2 IgM and IgG and Human IFN-γ SARS-CoV-2 ELISpot
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2021-002404-12
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on serology and ELISPOT test
-
ORIOL BESTARDCompletedKidney Transplantation | CMV InfectionSpain, Belgium
-
Chulalongkorn UniversityCompletedCephalosporin Allergy | Non-immediate Drug ReactionsThailand
-
University Health Network, TorontoOxford ImmunotecCompleted
-
Universidade de Cabo VerdeUniversity of Southern Denmark; European and Developing Countries Clinical... and other collaboratorsCompletedCOVID-19 | SARS-CoV-2 | BCG | Health Care WorkerCape Verde
-
Johns Hopkins Aramco HealthcareUnknown
-
Safaa SamirUnknown
-
Hôpital Européen MarseilleActive, not recruiting
-
Hospital St. Joseph, Marseille, FranceUnknown
-
Assiut UniversityUnknownHelicobacter Pylori Infection
-
Hôpital Européen MarseilleUnknownCovid19 | Virus-HIVFrance